41 studies found for:    PN400
Show Display Options
Rank Status Study
1 Completed
Has Results
A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO)
Condition: Gastric Ulcer
Interventions: Drug: PN400 (VIMOVO);   Drug: PN 400 (VIMOVO)
2 Completed Study Evaluating the Effect of Food on the Bioavailability of PN400 Components
Condition: Arthritis
Intervention: Drug: PN400
3 Completed
Has Results
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
Condition: Osteoarthritis
Interventions: Drug: PN 400 (VIMOVO);   Drug: celebrex;   Other: Placebo;   Drug: Rescue Antacid
4 Completed
Has Results
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
Condition: Osteoarthritis
Interventions: Drug: PN 400 (VIMOVO);   Drug: celebrex;   Drug: Placebo;   Drug: Rescue Antacid
5 Terminated
Has Results
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers in High Risk Subjects Compared to Arthrotec
Condition: Gastric Ulcer
Interventions: Drug: PN400 (VIMOVO);   Drug: Diclofenac/Misoprostol
6 Completed PK Study to Evaluate Esomeprazole Plasma Levels Following Administration of PN 400
Condition: Healthy
Intervention: Drug: PN400
7 Completed
Has Results
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Condition: Gastric Ulcer
Interventions: Drug: PN400 (VIMOVO);   Drug: Naproxen
8 Completed
Has Results
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Condition: Gastric Ulcer
Interventions: Drug: PN400 (VIMOVO);   Drug: Naproxen
9 Completed Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone
Condition: Healthy
Interventions: Drug: PN400;   Drug: Naprosyn
10 Completed Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Naprosyn E
Condition: Healthy
Interventions: Drug: PN400;   Drug: Naproxen
11 Completed A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
Condition: Arthritis
Interventions: Drug: PN 400;   Drug: EC naproxen plus EC esomeprazole;   Drug: EC naproxen;   Drug: EC esomeprazole
12 Completed A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
Condition: Platelet Inhibition
Interventions: Drug: PN400;   Drug: ASA;   Drug: Placebo
13 Completed Phase I Study to Evaluate Bioavailability of Naproxen as PN400 Compared to Naproxen as Proxen S and Naprosyn E
Condition: Healthy Volunteer
Interventions: Drug: PN400;   Drug: Naproxen (Proxen S);   Drug: Naproxen (Naprosyn E)
14 Completed Study Evaluating the Bioavailability of Naproxen 500 mg in Three Formulations
Condition: Arthritis
Interventions: Drug: PN400;   Drug: naproxen
15 Completed Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations
Condition: Arthritis
Interventions: Drug: PN400;   Drug: Naproxen
16 Terminated A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine
Condition: Otitis Media
Intervention: Biological: undecavalent pneumococcal-protein D conjugate vaccine
17 Not yet recruiting Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
Conditions: Squamous Cell Carcinoma of the Hypopharynx Stage III;   Squamous Cell Carcinoma of the Hypopharynx Stage IV;   Laryngeal Squamous Cell Carcinoma Stage III;   Laryngeal Squamous Cell Carcinoma Stage IV;   Oropharyngeal Squamous Cell Carcinoma Stage III;   Oropharyngeal Squamous Cell Carcinoma Stage IV;   Squamous Cell Carcinoma of the Oral Cavity Stage III;   Squamous Cell Carcinoma of the Oral Cavity Stage IV;   Locally Advanced Malignant Neoplasm
Interventions: Dietary Supplement: Standard care of parenteral nutrition;   Dietary Supplement: ZentroOLIMEL 5.7% parenteral over night;   Biological: Cetuximab;   Drug: Cisplatin;   Radiation: Radiotherapy
18 Completed
Has Results
Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants
Condition: Infections, Streptococcal
Interventions: Biological: Pneumococcal conjugate vaccine GSK2830929A;   Biological: Pneumococcal conjugate vaccine GSK2830930A;   Biological: Synflorix™;   Biological: Prevnar 13™;   Biological: Infanrix hexa™
19 Active, not recruiting CO(Mbined Therapy of Malignant) S(Alivary Gland tu)M(Ours With)I(MRT and) c(Arbon Ions): COSMIC
Conditions: Malignancy;   Salivary Glands;   Tumor
Intervention: Radiation: carbon ion boost
20 Completed Vitamin E for Oxaliplatin-induced Peripheral Neuropathy Prophylaxis
Condition: Peripheral Neuropathy
Interventions: Drug: Vitamin E;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years